The altered immunological milieu in cancer patients, characterized by dysregulated cytokine profiles, can modulate the expression of ACE2 and TMPRSS2, further impacting the course of SARS‐CoV‐2 infection [15]. This evidence concerns the gene TMPRSS2 and cancer.